VEGFC and neoplasm: In contrast to IgG control, chronic treatment with anti-NRP2B, anti-VEGF-C (VC1.12) or anti-VEGF-A antibodies significantly reduced pulsatile frequency in tumor-bearing animals (Figure 4), with anti-VEGF-C and -A exhibiting greater effect than anti-NRP2B.